Engrail Therapeutics, Inc.

Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. It is committed to rapidly advancing innovative, precision-targeted therapeutics, aiming to deliver transformational therapies for patients with devastating neuropsychiatric and neurodevelopmental disorders. Its pipeline has been built through strong partnerships and internal discovery capabilities, and it applies precision chemistry and pharmacology to develop targeted drugs.

Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. The company is committed to rapidly advancing its innovative, precision-targeted therapeutics. Its purpose is to deliver transformational therapies to improve the lives of patients with devastating neuropsychiatric and neurodevelopmental disorders. Engrail's pipeline has been built through strong partnerships and internal discovery capabilities, and it actively seeks strategic partnerships to drive the development and advancement of its pipeline.

Clinical-stage pharmaceutical company aspiring to become a leader in neuroscience, developing precision-targeted therapeutics for neuropsychiatric and neurodevelopmental disorders.

• 2021.02.14

  Reported2021.02.14

  Engrail acquires Neurocycle Therapeutics[5]Engrail收购Neurocycle Therapeuticssdbj.com

  San Diego-based Engrail Therapeutics acquired Neurocycle Therapeutics, a firm specializing in sub-type selective GABA-A modulation.

Read more

1. 1Precision Neuroscience, Transformational Therapies | Engrailengrail.com
2. 2About Us | Engrailengrail.com
3. 3Partners | Engrail Precision Neuroscienceengrail.com
4. 4Our Science | Engrail Precision Neuroscienceengrail.com
5. 5Engrail收购Neurocycle Therapeuticssdbj.com